Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01123395 · ClinicalTrials.gov registry record · Phase 1

Bioavailability Study of Colcrys® in Apple Juice

A Phase 1 study, sponsored by Mutual Pharmaceutical Company.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT01123395 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01123395, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and dissolved in apple juice relative to the same dose given as an intact tablet to healthy subjects following an overnight fast.

Interventions

  • DRUG colchicine 0.6 mg tablet

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2010-05
Est. Completion 2010-06
Phase Phase 1

Sponsor

Mutual Pharmaceutical Company

27 total trials

What the Registry Record Tells You About NCT01123395

The ClinicalTrials.gov registry entry for NCT01123395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which colchicine 0.6 mg tablet is the first listed.

NCT01123395 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01123395 about?

NCT01123395 is a clinical study titled "Bioavailability Study of Colcrys® in Apple Juice". The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and dissolved in apple juice relative to the same dose given as an intact tablet to healthy subjects following an overnight fast.

What is the current status of trial NCT01123395?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-05. Estimated completion is 2010-06.

What interventions are being tested in trial NCT01123395?

The interventions under investigation include: colchicine 0.6 mg tablet (DRUG).

Who is sponsoring clinical trial NCT01123395?

This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.